Clinical Trial

Neural Correlates During Alcohol Intoxication

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Alcohol intoxication is responsible for a large proportion of violent crime/assault and personal injury in our society. While a number of variables have been associated with alcohol-related aggression, high trait aggression and impaired executive function have been identified as key factors. Both Alcohol Use Disorder (AUD) and Impulsive Aggression behavior (AGG) are related to impaired social-emotional information processing (SEIP) whereby social threat cues, especially ones that are ambiguous in nature, lead to hostile attribution and negative emotional response to the "other" and, then, aggression against the "other". Thus, understanding the underlying neuroscience of SEIP under the influence of alcohol will be critical to identifying targets for intervention to reduce alcohol-related aggressive behavior. In addition to potential pharmacologic and cognitive-behavioral based interventions, such interventions may also involve the rehabilitation of aberrant neuronal circuits underlying social cognitive function through neuroplasticity-based remediation exercises. This study is designed to see how brain activation of cortico-limbic circuits involving social-emotional information processing, analyzed by fMRI Imaging, are impacted by alcohol administration in those with and without aggressive disorders and with and without alcohol use disorder.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-01.
Trial Details
NCT Number NCT06118580
Lead Sponsor Ohio State University
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions Alcohol Use Disorder, Intermittent Explosive Disorder
Enrollment 144 participants
Start Date 2023-06-08
Primary Completion 2025-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-27